Showing results (21-30 of 105) with videos related to

Sort By:
Pageof 11
European Journal of Haematology|June 25, 2019
Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myelomaKatarina Uttervall, Johanna Borg Bruchfeld, Charlotte Gran, et al.
Cancer Chemotherapy and Pharmacology|October 26, 2007
The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemiaLars Möllgård, Stefan Deneberg, Hareth Nahi, et al.
European Journal of Haematology|August 27, 2014
TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcomeIngrid Jakobsen Falk, Kerstin Willander, Roza Chaireti, et al.
Plos One|July 9, 2014
The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairmentKatarina Uttervall, Adil D Duru, Johan Lund, et al.
Plos One|September 18, 2015
Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple MyelomaAdil Doganay Duru, Tolga Sutlu, Ann Wallblom, et al.
Cancer Medicine|April 23, 2024
Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from SwedenKatarina Uttervall, Love Tätting, Konstantinos Lemonakis, et al.
British Journal of Haematology|September 16, 2006
Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimensMats Merup, Vladimir Lazarevic, Hareth Nahi, et al.
Oncology Reports|June 11, 2009
Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantationEsbjörn Paul, Tolga Sutlu, Stefan Deneberg, et al.
Leukemia & Lymphoma|July 24, 2009
Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survivalEsbjörn Paul, Esbjörn Paul, Bertil Uggla, et al.
Cancer Medicine|November 3, 2023
Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myelomaHareth Nahi, Gabriel Afram, Katarina Uttervall, et al.
Pageof 11